Table 4 Chemotherapy response assessment
| Â | Differentiation status | PLR | NLR | cNPS | cNPLDS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
well/moderate | poor | ≤223 | > 223 | ≤3.04 | > 3.04 | 1 | 2 | 3 | 1–2 | 3–4 | 6–9 | |
Total | 46 | 90 | 89 | 47 | 81 | 55 | 69 | 32 | 35 | 27 | 55 | 54 |
CR | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
PR | 3 (6.52%) | 4 (4.44%) | 4 (4.49%) | 3 (6.38%) | 3 (3.70%) | 4 (7.27%) | 2 (2.90%) | 3 (9.38%) | 2 (5.71%) | 2 (7.41%) | 1 (1.82%) | 4 (7.41%) |
SD | 36 (78.26%) | 64 (71.11%) | 72 (80.89%) | 28 (59.57%) | 68 (83.95%) | 32 (58.18%) | 59 (85.51%) | 22 (68.75%) | 17 (48.57%) | 23 (85.19%) | 46 (83.64%) | 31 (57.41%) |
PD | 7 (15.21%) | 22 (24.44%) | 13 (14.61%) | 16 (34.04%) | 10 (12.34%) | 19 (34.55%) | 8 (11.59%) | 7 (21.87%) | 14 (40%) | 2 (7.41%) | 8 (14.55%) | 19 (35.19%) |
DCR | 84.78% | 75.56% | 85.39% | 65.96% | 87.65% | 65.45% | 88.40% | 78.13% | 60% | 92.59% | 85.45% | 64.81% |
P | 0.214 | 0.008 | 0.002 | 0.004 | 0.004 | |||||||